# A Study of the Safety and Biological Activity of Intraperitoneal (IP) EGEN-001 Administered Alone and in Combination With Standard Chemotherapy in Colorectal Peritoneal Carcinomatosis Patients

> **NCT01300858** · PHASE1,PHASE2 · TERMINATED · sponsor: **EGEN, Inc.** · enrollment: 4 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** EGEN-001-301

## Key facts

- **NCT ID:** NCT01300858
- **Lead sponsor:** EGEN, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-06
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Sites could not enroll patients.
- **Last updated:** 2015-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01300858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01300858, "A Study of the Safety and Biological Activity of Intraperitoneal (IP) EGEN-001 Administered Alone and in Combination With Standard Chemotherapy in Colorectal Peritoneal Carcinomatosis Patients". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT01300858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*